An open-label, prospective, randomized comparison of Hirulog Vs. Heparin in patients receiving aspirin and thrombolysis (Streptokinase) for the treatment of acute myocardial infarction.

THE MEDICINES COMPANY, CAMBRIDGE M.A.,0 个研究点目标入组 0 人开始时间: 1998年2月19日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•Patients of any age with symptoms of acute myocardial infarction lasting more than 30 minutes and requesting medical support during the first 6 hours, and that have been shown to have at least 1mm of segment elevation are considered candidates for this study. ST in two or more leads of the precordial limbs or leads (V4-V6) or at least 2mm of ST-segment elevation in 2 or more contiguous precordial leads (V1-V3) in a 12-lead electrocardiogram, or the development of a new left branch block.

•-Active bleeding or known hemorrhagic diathesis.
•-History of CVA, dementia or damage to the central nervous system (for example neoplasia, aneurysm, arteriovenous malformation, intracranial or intraspinal surgery or trauma), or transient ischemic attacks within the previous six months.
•-Major surgery or significant trauma in the past six weeks.
•-Gastrointestinal bleeding within the past six weeks,
•-Vascular puncture not compressible within the previous two weeks.
•-Severe hypertension uncontrollable upon admission (blood pressure> 180 / 110mm Hg)
•-Concomitant use of oral anticoagulants
•-Previous administration of streptokinase
•-Use of any investigational drug in the past 30 days.

发起方

THE MEDICINES COMPANY, CAMBRIDGE M.A.,